Crunching the numbers for MCRB... Refresh in a moment for the full analysis.
Seres Therapeutics, Inc. (MCRB)
mixed
$8.32
Updated: 2026-04-13
53
TradeApes Score
hold
Financial Strength
75
Strong
Operating Trend
50
Mixed
Valuation
50
Mixed
Capital Allocation
30
Weak
Risk
50
Mixed
Key Findings
+
Low leverage — net debt/EBITDA below 1×
−
Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Add to Watchlist
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.